PERFORMANCE OF DIFFERENT SURVIVAL MODELS FOR EXTRAPOLATION OF IMMATURE OS DATA FOR 2L+NSCLC THERAPIES

被引：0
|
作者：
Jacob, J. [1 ]
Vandoulakis, M. [2 ]
Klint, J. [3 ]
机构：
[1] IQVIA, London, LON, England
[2] IQVIA, Athens, Greece
[3] Dauchi Sankyo, Munich, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
MSR139
引用
收藏
页码：S419 / S420
页数：2
相关论文
共 15 条
  • [1] The Extrapolation Performance of Survival Models for Data With a Cure Fraction: A Simulation Study
    Kearns, Benjamin
    Stevenson, Matt D.
    Triantafyllopoulos, Kostas
    Manca, Andrea
    [J]. VALUE IN HEALTH, 2021, 24 (11) : 1634 - 1642
  • [2] PERFORMANCE OF AIC AND BIC FOR THE EXTRAPOLATION OF SURVIVAL DATA WITH DIFFERENT LEVELS OF CENSORING
    Butepage, G.
    Vitor, C.
    Carlqvist, P.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S363 - S363
  • [3] Long-Term Survival in Atezolizumab-Treated Patients with 2L+NSCLC from Ph III Randomized OAK Study
    Satouchi, M.
    Fehrenbacher, L.
    Dols, M. Cobo
    Han, J.
    Von Pawel, J.
    Bordoni, R.
    Hida, T.
    Park, K.
    Moro-Sibilot, D.
    Conkling, P.
    Matheny, C.
    Yu, W.
    He, P.
    Kowanetz, M.
    Gandhi, M.
    Ballinger, M.
    Sandler, A.
    Gandara, D. R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1794 - S1794
  • [4] 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+NSCLC (POPLAR)
    Mazieres, J.
    Park, K.
    Lewanski, C.
    Gadgeel, S.
    Fehrenbacher, L.
    Rittmeyer, A.
    Han, J-Y.
    Artal-Cortes, A.
    Braiteh, F.
    Vansteenkiste, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S79 - S79
  • [5] 4-Year Survival in Randomised Phase II (POPLAR) and Phase III (OAK) Studies of Atezolizumab vs. Docetaxel in 2L+NSCLC
    Mazieres, J.
    Rittmeyer, A.
    Gadgeel, S. M.
    Hida, T.
    Gandara, D.
    Cortinovis, D.
    Barlesi, F.
    Yu, W.
    Matheny, C.
    Ballinger, M.
    Park, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S15 - S15
  • [6] BAYESIAN HIERARCHICAL MODEL-BASED NETWORK META-ANALYSIS TO OVERCOME SURVIVAL EXTRAPOLATION CHALLENGES CAUSED BY IMMATURE DATA: APPLICATION IN PREVIOUSLY TREATED METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) PD-L1>1%
    Heeg, B.
    Verhoek, A.
    Tremblay, G.
    Chu, H.
    Roychoudhury, S.
    Cappelleri, J.
    Harari, O.
    Soltanifar, M.
    Ouwens, M.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S364 - S365
  • [7] ADJUSTMENT FOR THE IMPACT OF SUBSEQUENT THERAPIES NOT AVAILABLE IN UK ON OVERALL SURVIVAL (OS) IN CASTOR TRIAL: A SUBGROUP ANALYSIS IN SECOND-LINE (2L) PATIENTS
    Van Sanden, S.
    Perualila, N.
    Diels, J.
    Trevor, N.
    Pei, H.
    Anjo, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S400 - S400
  • [8] THE RESPONSE OF DIPLOID YEAST TO RADIATIONS AT DIFFERENT LET .2. ANALYSIS OF SURVIVAL-DATA WITH VARIOUS MODELS OF RADIATION ACTION
    BERTSCHE, U
    LACHET, B
    [J]. RADIATION RESEARCH, 1980, 84 (01) : 53 - 64
  • [9] Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study
    Yang, Y.
    Wang, Z.
    Fang, J.
    Yu, Q.
    Han, B.
    Cang, S.
    Chen, G.
    Mei, X.
    Yang, Z.
    Stefaniak, V.
    Lin, Y.
    Wang, S.
    Zhang, W.
    Sun, L.
    Zhang, Y.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S28 - S28
  • [10] Overall survival (OS) by EGFR mutation status and subtypes (Deletion 19/L858R) for first-line therapies with maintenance regimens in advanced non-small-cell lung cancer (NSCLC): a Bayesian multiple treatment comparison (MTC) meta-analysis
    Tan, P. S.
    Lopes, G.
    Aacharyya, S.
    Bilger, M.
    Haaland, B.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 135 - 135
12